Stock Analysis on Net
Stock Analysis on Net

DexCom Inc. (NASDAQ:DXCM)

This company has been moved to the archive! The financial data has not been updated since October 26, 2023.

Price to FCFE (P/FCFE)

Microsoft Excel

Free Cash Flow to Equity (FCFE)

DexCom Inc., FCFE calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income (loss) 341,200 154,700 493,600 101,100 (127,100)
Net noncash charges 301,600 419,800 2,800 207,300 291,200
Changes in operating assets and liabilities 26,700 (132,000) (20,800) 6,100 (40,900)
Net cash provided by operating activities 669,500 442,500 475,600 314,500 123,200
Purchases of property and equipment (364,800) (389,200) (199,000) (180,000) (67,100)
Proceeds from issuance of convertible notes, net of issuance costs — — 1,188,800 — 836,600
Repurchase of convertible notes — — (282,600) — —
Free cash flow to equity (FCFE) 304,700 53,300 1,182,800 134,500 892,700

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The period from 2018 to 2022 demonstrates a marked divergence between steady operational cash growth and highly volatile free cash flow to equity (FCFE). While the capacity to generate cash from core business operations expanded consistently, the actual cash available to shareholders fluctuated significantly, indicating substantial shifts in capital expenditures and financing activities.

Operating Cash Flow Progression
A sustained upward trend in net cash provided by operating activities is observed, increasing from 123,200 thousand US dollars in 2018 to 669,500 thousand US dollars by 2022. This represents a significant expansion in the capacity to generate liquidity from primary business functions, with only a marginal contraction occurring in 2021 before reaching a five-year peak in 2022.
FCFE Volatility and Fluctuations
Free cash flow to equity exhibits extreme instability over the analyzed period. Peak values were recorded in 2018 (892,700 thousand US dollars) and 2020 (1,182,800 thousand US dollars), which contrast sharply with significant troughs in 2019 (134,500 thousand US dollars) and 2021 (53,300 thousand US dollars). The absence of a linear trend in FCFE suggests that the cash available to equity holders is heavily influenced by non-operational cash movements.
Operational vs. Equity Cash Flow Divergence
A notable disconnect exists between operating cash and FCFE. In 2018 and 2020, FCFE significantly exceeded operating cash flow, which typically indicates substantial cash inflows from financing activities, such as debt issuance, or a significant decrease in capital expenditures. Conversely, in 2021 and 2022, FCFE remained below operating cash flow, suggesting that capital investments or debt repayments outweighed financing inflows during these periods.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Price to FCFE Ratio, Current

DexCom Inc., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel
No. shares of common stock outstanding 386,373,935
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands) 304,700
FCFE per share 0.79
Current share price (P) 81.09
Valuation Ratio
P/FCFE 102.83
Benchmarks
P/FCFE, Competitors1
Abbott Laboratories 31.33
Elevance Health Inc. 24.43
Intuitive Surgical Inc. 60.69
Medtronic PLC 28.71
UnitedHealth Group Inc. 21.73
P/FCFE, Sector
Health Care Equipment & Services 15.71
P/FCFE, Industry
Health Care 26.69

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.


Price to FCFE Ratio, Historical

DexCom Inc., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 386,413,690 388,262,536 384,709,452 366,376,568 360,007,068
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)2 304,700 53,300 1,182,800 134,500 892,700
FCFE per share3 0.79 0.14 3.07 0.37 2.48
Share price1, 4 107.24 101.75 102.55 63.05 36.56
Valuation Ratio
P/FCFE5 136.00 741.20 33.35 171.75 14.74
Benchmarks
P/FCFE, Competitors6
Abbott Laboratories 26.11 24.52 — — —
Elevance Health Inc. 14.26 11.07 — — —
Intuitive Surgical Inc. 89.67 58.39 — — —
Medtronic PLC 19.71 38.91 — — —
UnitedHealth Group Inc. 12.57 20.11 — — —
P/FCFE, Sector
Health Care Equipment & Services 16.47 22.14 — — —
P/FCFE, Industry
Health Care 18.50 17.94 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2022 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 304,700,000 ÷ 386,413,690 = 0.79

4 Closing price as at the filing date of DexCom Inc. Annual Report.

5 2022 Calculation
P/FCFE = Share price ÷ FCFE per share
= 107.24 ÷ 0.79 = 136.00

6 Click competitor name to see calculations.


An analysis of the equity valuation metrics reveals a significant divergence between share price appreciation and the stability of Free Cash Flow to Equity (FCFE). While the market price of the shares exhibits a consistent upward trajectory, the underlying FCFE per share demonstrates extreme volatility, leading to erratic fluctuations in the P/FCFE ratio.

Share Price Trend
The share price experienced substantial growth over the five-year period, rising from 36.56 US$ in 2018 to 107.24 US$ by 2022. The most aggressive expansion occurred between 2018 and 2020, followed by a period of relative stabilization where the price remained above 100 US$.
FCFE per Share Performance
Cash flow to equity has been characterized by instability. After starting at 2.48 US$ in 2018, the value dropped sharply to 0.37 US$ in 2019, recovered to a peak of 3.07 US$ in 2020, and plummeted to a period low of 0.14 US$ in 2021, before finishing at 0.79 US$ in 2022.
P/FCFE Ratio Interpretation
The P/FCFE ratio exhibits extreme variance, largely driven by the volatility of the FCFE per share rather than movements in the share price. The ratio reached anomalous peaks of 171.75 in 2019 and 741.20 in 2021. These spikes correlate directly with years of diminished cash flow, indicating that the valuation ratio is highly sensitive to fluctuations in the company's ability to generate free cash flow for equity holders.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?